Neuren’s Phase 2 trial of trofinetide demonstrates significant clinical benefit in paediatric Rett syndrome
Today (22 March 2017), Neuren Pharmaceuticals announced to the Australian Stock Exchange in Melbourne that its Phase 2 trial of treatment of Rett syndrome girls aged from 5 to 15 years with trofinetide, showed that it was of benefit for them. Neuren's actual announcement can be viewed by clicking on…
